NEW YORK, Sept. 27, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: <\/p>\n
Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules <\/p>\n
http:\/\/www.reportlinker.com\/p01006955\/Therapy-Trends--Multiple-Sclerosis----KOL-Insight--and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> <\/p>\n Charting the Future Multiple Sclerosis Market Landscape <\/p>\n Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies. <\/p>\n Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources: <\/p>\n An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance <\/p>\n A detailed forecast data analysis spreadsheet model comparing critical market parameters including <\/p>\n Timely event-driven market forecast report and data analysis updates over the next 12 months <\/p>\n Mapping Future Events to Product Sales Forecasts <\/p>\n<\/p>\n See the original post here: NEW YORK, Sept. 27, 2012 \/PRNewswire\/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules http:\/\/www.reportlinker.com\/p01006955\/Therapy-Trends--Multiple-Sclerosis----KOL-Insight--and-Consensus-Outlook-Modules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology<\/a> Charting the Future Multiple Sclerosis Market Landscape Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies Continue reading
\nTherapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"